SCHEMBL20813392

SCHEMBL20813392

Ic1cc(-c2ccncn2)ncn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 1/20 0.52
▸ GRM5 P41594 2/20 0.45
▸ GSK3B P49841 5/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ CYP2D6 P10635 1/20 0.35
▸ MAPK14 Q16539 2/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ LATS1 O95835 1/20 0.35
▸ LATS2 Q9NRM7 1/20 0.35
▸ MAPK9 P45984 3/20 0.33
▸ MAP4K4 O95819 2/20 0.33
▸ EGFR P00533 2/20 0.33
▸ FRK P42685 2/20 0.33
▸ CSNK1A1 P48729 2/20 0.33
▸ CDC7 O00311 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ ROCK1 Q13464 1/20 0.33
▸ CDC42BPB Q9Y5S2 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ DCLK1 O15075 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20813389 0.79 MIF (0.68) MIFGRM5MAP4K4HDAC8
SCHEMBL2814353 0.79 HSP90AA1 (0.52) GRM5GSK3BHSP90AA1CYP2D6MAPK14
SCHEMBL30595872 0.79 HSP90AA1 (0.52) GRM5GSK3BHSP90AA1CYP2D6MAPK14
SCHEMBL20813388 0.78 MIF (0.60) MIFGRM5HSP90AA1HDAC8
SCHEMBL16397837 0.75 GRM5 (0.45) GRM5GSK3BHSP90AA1CYP2D6MAPK14
SCHEMBL30448395 0.75 HSP90AA1 (0.58) GRM5GSK3BHSP90AA1CYP2D6MAPK14
SCHEMBL16398730 0.75 GRM5 (0.50) GRM5GSK3BHSP90AA1CYP2D6MAPK14
SCHEMBL27109835 0.75 GRM5 (0.45) GRM5GSK3BHSP90AA1CYP2D6LATS1
SCHEMBL10402322 0.74 HSP90AA1 (0.48) GRM5GSK3BHSP90AA1CYP2D6MAPK14
SCHEMBL171767 0.74 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4327882-A2 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER The Board of Trustees of the Leland Stanford Junior University (US) 2024-02-28 — — EP disclosed
WO-2023077083-A1 ENPP1 INHIBITORS AS INHIBITORS OF METASTASIS ANGARUS THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
WO-2021226136-A1 ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE ANGARUS THERAPEUTICS, INC. (US) 2021-11-11 — — WO disclosed
WO-2019051269-A1 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2019-03-14 — — WO disclosed
Send feedback